Transactions
16
Insider / AMGEN INC
Kullman Ellen Jamison
Director at AMGEN INC
- Company
- AMGEN INC
- First filing on record
- October 2, 2025
- Latest trade on record
- September 24, 2026
- SEC filings
- EDGAR ↗
Kullman Ellen Jamison, Director at AMGEN INC, has disclosed 16 transactions in DELL, AMGN since October 2, 2025: 0 purchases (0 open-market buys) and 5 sales, worth about $37.2M at the reported prices. The latest was filed September 28, 2026, 4 days after the trade.
Open-market buys
0
Sales
5
Avg. disclosure lag
3.4d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Kullman Ellen Jamison made no purchases and 4 sales worth $22M, plus 8 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Kullman Ellen Jamison has traded 1 stock on record; the largest by dollars is DELL.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 5 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 8 | 460,304 | $3.2M |
| S | Open-market sale | 5 | 230,152 | $34.1M |
| A | Grant or award | 3 | 2,671 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 12 | 0 | 4 · $21.8M |
| 2025 | 4 | 0 | 1 · $12.3M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| DELL | Other A | September 24, 2026 | September 28, 2026 | 4d | 419 | — | — | Form 4 ↗ | ||
| AMGN | Other A | May 19, 2026 | May 21, 2026 | 2d | 665 | — | — | Form 4 ↗ | ||
| DELL | Option / conversion M | March 6, 2026 | March 10, 2026 | 4d | 126,258 | — | — | derivative | Form 4 ↗ | |
| DELL | Option / conversion M | March 6, 2026 | March 10, 2026 | 4d | 15,287 | — | — | derivative | Form 4 ↗ | |
| DELL | Option / conversion M | March 6, 2026 | March 10, 2026 | 4d | 8,801 | — | — | derivative | Form 4 ↗ | |
| DELL | Sell S | March 6, 2026 | March 10, 2026 | 4d | 69,127 | $145 | $10.1M | Form 4 ↗ | ||
| DELL | Sell S | March 6, 2026 | March 10, 2026 | 4d | 57,131 | $145 | $8.3M | Form 4 ↗ | ||
| DELL | Option / conversion M | March 6, 2026 | March 10, 2026 | 4d | 126,258 | $14 | $1.7M | Form 4 ↗ | ||
| DELL | Sell S | March 6, 2026 | March 10, 2026 | 4d | 15,287 | $146 | $2.2M | Form 4 ↗ | ||
| DELL | Option / conversion M | March 6, 2026 | March 10, 2026 | 4d | 15,287 | $14 | $208K | Form 4 ↗ | ||
| DELL | Sell S | March 6, 2026 | March 10, 2026 | 4d | 8,801 | $146 | $1.3M | Form 4 ↗ | ||
| DELL | Option / conversion M | March 6, 2026 | March 10, 2026 | 4d | 8,801 | $14 | $123K | Form 4 ↗ | ||
| DELL | Option / conversion M | October 15, 2025 | October 17, 2025 | 2d | 79,806 | — | — | derivative | Form 4 ↗ | |
| DELL | Sell S | October 15, 2025 | October 17, 2025 | 2d | 79,806 | $154 | $12.3M | Form 4 ↗ | ||
| DELL | Option / conversion M | October 15, 2025 | October 17, 2025 | 2d | 79,806 | $14 | $1.1M | Form 4 ↗ | ||
| DELL | Other A | September 30, 2025 | October 2, 2025 | 2d | 1,587 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| September 28, 2026 | Form 4 | 0001303141-26-000008 | 1 | published | EDGAR ↗ |
| May 21, 2026 | Form 4 | 0000318154-26-000107 | 1 | published | EDGAR ↗ |
| March 10, 2026 | Form 4 | 0001303141-26-000006 | 10 | published | EDGAR ↗ |
| October 17, 2025 | Form 4 | 0001303141-25-000009 | 3 | published | EDGAR ↗ |
| October 2, 2025 | Form 4 | 0001303141-25-000007 | 1 | published | EDGAR ↗ |
Other insiders at AMGEN INC
- Silver Lake Partners IV, L.P. Director 559 rows
- SL SPV-2, L.P. Director 519 rows
- Silver Lake Partners V DE (AIV), L.P. Director 514 rows
- Silver Lake Technology Investors IV, L.P. Director 507 rows
- Silver Lake Technology Investors V, L.P. Director 507 rows
- SLTA IV (GP), L.L.C. Director 417 rows
- SLTA V (GP), L.L.C. Director 417 rows
- Radakovich Lynn Vojvodich Director 28 rows
- GREEN WILLIAM D Director 24 rows
- Grygiel Nancy A. SVP & CCO 21 rows
Everyone on file, with contracts and lobbying under the company's name: AMGEN INC.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 5 | 16 | October 2, 2025 | September 28, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.